Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2023-10-31
DOI
10.1080/13543784.2023.2277389
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference
- (2023) Marc G. Ghany et al. HEPATOLOGY
- Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials
- (2023) Ed Gane et al. JOURNAL OF HEPATOLOGY
- Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study
- (2023) Jenn Singh et al. JOURNAL OF HEPATOLOGY
- Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
- (2023) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis B virus variants that contain mismatches in the bepirovirsen binding site
- (2023) Alexander Koenig et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up
- (2023) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
- (2023) Adrian Gadano et al. JOURNAL OF HEPATOLOGY
- Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study)
- (2023) Jerome Bouquet et al. JOURNAL OF HEPATOLOGY
- Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial
- (2023) Edward J. Gane et al. JOURNAL OF HEPATOLOGY
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
- (2022) Rex Wan-Hin Hui et al. Clinical and Molecular Hepatology
- A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV ‘cure’
- (2022) Kosh Agarwal et al. JOURNAL OF HEPATOLOGY
- Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: phase 2b analysis to inform phase 3 decision-making
- (2022) Amir Youssef et al. JOURNAL OF HEPATOLOGY
- Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study
- (2022) Shihyun You et al. JOURNAL OF HEPATOLOGY
- Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
- (2022) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
- (2022) Kelong Han et al. Clinical Pharmacology in Drug Development
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
- (2022) Man-Fung Yuen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B
- (2021) Edward Gane et al. HEPATOLOGY
- Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
- (2021) Man-Fung Yuen et al. NATURE MEDICINE
- Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
- (2021) Grishma Hirode et al. GASTROENTEROLOGY
- Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis
- (2020) Ryan T. Anderson et al. Clinical Gastroenterology and Hepatology
- Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
- (2020) Milan J. Sonneveld et al. Clinical Gastroenterology and Hepatology
- Fibrosis evolution in chronic hepatitis B E‐antigen negative patients across a 10‐year interval
- (2019) Lung‐Yi Mak et al. JOURNAL OF VIRAL HEPATITIS
- Guidance for design and endpoints of clinical trials in chronic hepatitis B ‐ Report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference
- (2019) Markus Cornberg et al. HEPATOLOGY
- Costs of viral hepatitis B in the Republic of Korea, 2002‐2015
- (2019) Dahye Baik et al. JOURNAL OF VIRAL HEPATITIS
- A large real‐world cohort study examining the effects of long‐term entecavir on hepatocellular carcinoma and HBsAg seroclearance
- (2019) Kwan‐Lung Ko et al. JOURNAL OF VIRAL HEPATITIS
- Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
- (2018) Wen-Juei Jeng et al. HEPATOLOGY
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: A Systematic Review
- (2018) Jiaye Liu et al. HEPATOLOGY
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
- (2017) Yuk-Fai Lam et al. Clinical and Translational Gastroenterology
- Lack of Interactions Between an Antisense Oligonucleotide with 2′-O-(2-Methoxyethyl) Modifications and Major Drug Transporters
- (2016) Rosie Z. Yu et al. Nucleic Acid Therapeutics
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
- (2015) S. K. Sarin et al. Hepatology International
- Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
- (2014) Maria Buti et al. DIGESTIVE DISEASES AND SCIENCES
- Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients
- (2013) T. Hara et al. JOURNAL OF VIRAL HEPATITIS
- HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma
- (2008) Man–Fung Yuen et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started